Ontology highlight
ABSTRACT:
SUBMITTER: Hockings H
PROVIDER: S-EPMC10196552 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Hockings Helen H Miller Rowan E RE
Therapeutic advances in medical oncology 20230516
The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease settings; therefore, most patients will receive PARPi at some point in their treatment pathway. The majority of this expanding population of patients eventually acquire resistance to PARPi, in addition to those with primary PARPi resistance. We discuss the rationale behind develop ...[more]